SG Americas Securities’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-18,927
| Closed | -$67K | – | 3220 |
|
|
2025
Q4 | $67K | Buy |
18,927
+7,987
| +73% | +$48.9K | ﹤0.01% | 3312 |
|
|
2025
Q3 | $97K | Buy |
+10,940
| New | +$111K | ﹤0.01% | 3092 |
|
|
2025
Q2 | – | Sell |
-25,242
| Closed | -$217K | – | 2939 |
|
|
2025
Q1 | $217K | Sell |
25,242
-9,602
| -28% | -$90.7K | ﹤0.01% | 2475 |
|
|
2024
Q4 | $374K | Buy |
34,844
+7,138
| +26% | +$54.9K | ﹤0.01% | 1604 |
|
|
2024
Q3 | $157K | Buy |
27,706
+14,272
| +106% | +$82.3K | ﹤0.01% | 2679 |
|
|
2024
Q2 | $57K | Buy |
+13,434
| New | +$54.3K | ﹤0.01% | 2654 |
|
|
2024
Q1 | – | Sell |
-307,568
| Closed | -$2.86M | – | 2972 |
|
|
2023
Q4 | $2.86M | Buy |
307,568
+38,155
| +14% | +$263K | 0.03% | 528 |
|
|
2023
Q3 | $1.76M | Buy |
+269,413
| New | +$2.14M | 0.02% | 825 |
|
|
2023
Q2 | – | Sell |
-31,382
| Closed | -$269K | – | 2310 |
|
|
2023
Q1 | $269K | Buy |
31,382
+14,309
| +84% | +$143K | ﹤0.01% | 2198 |
|
|
2022
Q4 | $158K | Buy |
17,073
+2,615
| +18% | +$27.9K | ﹤0.01% | 2381 |
|
|
2022
Q3 | $149K | Sell |
14,458
-19,036
| -57% | -$201K | ﹤0.01% | 2552 |
|
|
2022
Q2 | $335K | Buy |
+33,494
| New | +$317K | ﹤0.01% | 2307 |
|
|
2022
Q1 | – | Sell |
-12,550
| Closed | -$218K | – | 2964 |
|
|
2021
Q4 | $218K | Sell |
12,550
-12,656
| -50% | -$240K | ﹤0.01% | 2627 |
|
|
2021
Q3 | $452K | Buy |
+25,206
| New | +$502K | ﹤0.01% | 2596 |
|
|
2021
Q2 | – | Sell |
-10,419
| Closed | -$156K | – | 2854 |
|
|
2021
Q1 | $156K | Buy |
+10,419
| New | +$114K | ﹤0.01% | 2833 |
|
|
2018
Q1 | – | Sell |
-21,389
| Closed | -$69K | – | 3233 |
|
|
2017
Q4 | $69K | Buy |
+21,389
| New | +$84.2K | ﹤0.01% | 2928 |
|
|
2016
Q2 | – | Sell |
-12,700
| Closed | -$62K | – | 2595 |
|
|
2016
Q1 | $62K | Buy |
+12,700
| New | +$55.9K | ﹤0.01% | 2736 |
|
Other funds holding AVXL
VCM
SF
VPM